Literature DB >> 22012391

Chemical biology: Many faces of a cancer-supporting protein.

John F Darby, Paul Workman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22012391     DOI： 10.1038/478334b

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

Authors:  Kamalika Moulick; James H Ahn; Hongliang Zong; Anna Rodina; Leandro Cerchietti; Erica M Gomes DaGama; Eloisi Caldas-Lopes; Kristin Beebe; Fabiana Perna; Katerina Hatzi; Ly P Vu; Xinyang Zhao; Danuta Zatorska; Tony Taldone; Peter Smith-Jones; Mary Alpaugh; Steven S Gross; Nagavarakishore Pillarsetty; Thomas Ku; Jason S Lewis; Steven M Larson; Ross Levine; Hediye Erdjument-Bromage; Monica L Guzman; Stephen D Nimer; Ari Melnick; Len Neckers; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2011-09-25       Impact factor: 15.040

2.  Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches.

Authors:  Amie J McClellan; Yu Xia; Adam M Deutschbauer; Ron W Davis; Mark Gerstein; Judith Frydman
Journal:  Cell       Date:  2007-10-05       Impact factor: 41.582

3.  Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone.

Authors:  Rongmin Zhao; Mike Davey; Ya-Chieh Hsu; Pia Kaplanek; Amy Tong; Ainslie B Parsons; Nevan Krogan; Gerard Cagney; Duy Mai; Jack Greenblatt; Charles Boone; Andrew Emili; Walid A Houry
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

4.  HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Authors:  Shanu Modi; Alison Stopeck; Hannah Linden; David Solit; Sarat Chandarlapaty; Neal Rosen; Gabriella D'Andrea; Maura Dickler; Mary E Moynahan; Steven Sugarman; Weining Ma; Sujata Patil; Larry Norton; Alison L Hannah; Clifford Hudis
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

5.  Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

Authors:  Lecia V Sequist; Scott Gettinger; Neil N Senzer; Renato G Martins; Pasi A Jänne; Rogerio Lilenbaum; Jhanelle E Gray; A John Iafrate; Ryohei Katayama; Nafeeza Hafeez; Jennifer Sweeney; John R Walker; Christian Fritz; Robert W Ross; David Grayzel; Jeffrey A Engelman; Darrell R Borger; Guillermo Paez; Ronald Natale
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

6.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Authors:  Adeela Kamal; Lia Thao; John Sensintaffar; Lin Zhang; Marcus F Boehm; Lawrence C Fritz; Francis J Burrows
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

Review 7.  Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.

Authors:  Paul Workman
Journal:  Cancer Lett       Date:  2004-04-08       Impact factor: 8.679

8.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

Authors:  L Whitesell; E G Mimnaugh; B De Costa; C E Myers; L M Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

9.  Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

Authors:  Alison Maloney; Paul A Clarke; Soren Naaby-Hansen; Rob Stein; Jens-Oliver Koopman; Akunna Akpan; Alice Yang; Marketa Zvelebil; Rainer Cramer; Lindsay Stimson; Wynne Aherne; Udai Banerji; Ian Judson; Swee Sharp; Marissa Powers; Emmanuel deBilly; Joanne Salmons; Michael Walton; Al Burlingame; Michael Waterfield; Paul Workman
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

10.  Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.

Authors:  Bonnie Tillotson; Kelly Slocum; John Coco; Nigel Whitebread; Brian Thomas; Kip A West; John MacDougall; Jie Ge; Janid A Ali; Vito J Palombella; Emmanuel Normant; Julian Adams; Christian C Fritz
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157
  10 in total
  7 in total

Review 1.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

Review 2.  Chaperome heterogeneity and its implications for cancer study and treatment.

Authors:  Tai Wang; Anna Rodina; Mark P Dunphy; Adriana Corben; Shanu Modi; Monica L Guzman; Daniel T Gewirth; Gabriela Chiosis
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

Review 3.  Chaperome Networks - Redundancy and Implications for Cancer Treatment.

Authors:  Pengrong Yan; Tai Wang; Monica L Guzman; Radu I Peter; Gabriela Chiosis
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 4.  Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.

Authors:  Komal Jhaveri; Stefan O Ochiana; Mark Ps Dunphy; John F Gerecitano; Adriana D Corben; Radu I Peter; Yelena Y Janjigian; Erica M Gomes-DaGama; John Koren; Shanu Modi; Gabriela Chiosis
Journal:  Expert Opin Investig Drugs       Date:  2014-03-26       Impact factor: 6.206

5.  Probing molecular mechanisms of the Hsp90 chaperone: biophysical modeling identifies key regulators of functional dynamics.

Authors:  Anshuman Dixit; Gennady M Verkhivker
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

6.  What is known about melatonin, chemotherapy and altered gene expression in breast cancer.

Authors:  Carlos Martínez-Campa; Javier Menéndez-Menéndez; Carolina Alonso-González; Alicia González; Virginia Álvarez-García; Samuel Cos
Journal:  Oncol Lett       Date:  2017-02-10       Impact factor: 2.967

7.  Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes.

Authors:  Tony Taldone; Anna Rodina; Erica M DaGama Gomes; Matthew Riolo; Hardik J Patel; Raul Alonso-Sabadell; Danuta Zatorska; Maulik R Patel; Sarah Kishinevsky; Gabriela Chiosis
Journal:  Beilstein J Org Chem       Date:  2013-03-15       Impact factor: 2.883
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.